drugset / Trial / NCT03613428
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
NaSingle-groupOpen-labelTreatment
Summary
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib in combination with L-ASP, vincristine, and prednisone (LVP) in patients with relapsed-and-refractory (R/R) early T precursor acute lymphocytic leukemia (ETP-ALL). Once determined, the purpose of this study will be to determine the efficacy of ruxolitinib in combination with LVP in patients with R/R ETP-ALL.
Timeline
- Start
- 2018-12-01
- Primary completion
- 2020-12-30
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 80 mg | Oral |
| Background | Prednisone | Other / unclassified | 1 mg/kg | Oral |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |